This post was originally shared by Femtech Insider on June 26, 2025. Read the original post here.
Juniper Genomics has launched with $4.6 million in seed funding to commercialize what it describes as the first embryo screening test using whole genome and transcriptome sequencing. The Canada-based company aims to establish a new clinical standard for IVF genetic testing by analyzing millions of genetic markers compared to traditional platforms.
Company Ventures led the round, with participation from Innospark Ventures, MBX Capital, Amboy Street Ventures, Dria Ventures, and Blue Collective. The funding will support commercial expansion, team growth, and ongoing research partnerships as Juniper rolls out to early adopter clinics across North America.
Founded by Jeremy Grushcow, PhD, JD (CEO), Carolyn Quinlan, MSc (VP of Bioethics), and Dr. Lee Shulman (Medical Director), Juniper combines whole genome and transcriptome sequencing with trio analysis including both biological parents. The platform screens for specific genetic changes linked to IVF failure, miscarriage, and medical conditions after birth.
“The IVF journey can be emotionally exhausting and financially overwhelming—and the current standard of care for embryo testing has a low success rate that often leaves patients with more questions than answers,” said Grushcow. “We can do better by improving the chances of success on the very first try.”
Juniper differentiates itself by avoiding polygenic risk scores, instead focusing on specific genetic variants known to cause adverse pregnancy outcomes and serious health conditions. The company argues that polygenic scores, which assess fewer than 1,000 data points, provide statistical associations rather than predictive outcomes for individual embryos.
The testing process integrates into existing IVF workflows through standard day 5 or 6 embryo biopsies paired with parental blood draws. Juniper’s analysis examines thousands of clinically relevant genetic variants, positioning the test as replacing multiple existing preimplantation genetic testing methods.
“Juniper is addressing one of the most emotionally and financially challenging aspects of healthcare with a solution that is both scientifically advanced and deeply compassionate,” said Margaret Davidson, Principal at Company Ventures. “Their approach has the potential to establish a new benchmark in IVF.”
The platform enters an increasingly competitive embryo screening market where companies are expanding beyond basic chromosome analysis to include complex trait assessment. Juniper’s emphasis on avoiding controversial polygenic scoring while providing comprehensive genetic analysis represents a different approach to the expanding embryo selection capabilities.
The company has received support from Genome Canada and Genome Quebec GAPP grant funding alongside private investment, indicating both public and private sector interest in advancing embryo screening technology while maintaining ethical standards in reproductive medicine.